Squarepoint Ops LLC Acquires 56,743 Shares of AnaptysBio, Inc. $ANAB

Squarepoint Ops LLC grew its stake in shares of AnaptysBio, Inc. (NASDAQ:ANAB) by 21.2% during the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 324,446 shares of the biotechnology company’s stock after purchasing an additional 56,743 shares during the quarter. Squarepoint Ops LLC’s holdings in AnaptysBio were worth $21,900,000 at the end of the most recent quarter.

Several other hedge funds have also bought and sold shares of ANAB. Vanguard Group Inc. boosted its holdings in shares of AnaptysBio by 4.5% during the fourth quarter. Vanguard Group Inc. now owns 1,544,037 shares of the biotechnology company’s stock worth $74,855,000 after acquiring an additional 67,048 shares during the period. Hsbc Holdings PLC acquired a new stake in AnaptysBio during the 1st quarter worth approximately $7,137,000. Sofinnova Investments Inc. boosted its stake in AnaptysBio by 13.1% in the 4th quarter. Sofinnova Investments Inc. now owns 287,690 shares of the biotechnology company’s stock valued at $13,947,000 after purchasing an additional 33,422 shares during the period. Bank of New York Mellon Corp bought a new stake in shares of AnaptysBio in the second quarter valued at about $3,807,000. Finally, Bank of America Corp DE grew its position in shares of AnaptysBio by 283.2% during the 1st quarter. Bank of America Corp DE now owns 501,086 shares of the biotechnology company’s stock worth $27,790,000 after purchasing an additional 370,319 shares in the last quarter.

AnaptysBio Stock Performance

ANAB stock opened at $56.60 on Wednesday. The stock’s 50 day simple moving average is $57.78 and its 200 day simple moving average is $59.27. The company has a market cap of $1.68 billion, a P/E ratio of -52.41 and a beta of 0.71. AnaptysBio, Inc. has a fifty-two week low of $11.40 and a fifty-two week high of $72.36.

Analysts Set New Price Targets

ANAB has been the topic of several analyst reports. Wolfe Research reissued an “outperform” rating and set a $78.00 target price on shares of AnaptysBio in a report on Monday, August 31st. Zacks Research downgraded AnaptysBio from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, June 2nd. Leerink Partners set a $90.00 target price on shares of AnaptysBio in a report on Friday, May 15th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of AnaptysBio in a research report on Friday, August 7th. Finally, Wall Street Zen cut AnaptysBio from a “strong-buy” rating to a “hold” rating in a report on Saturday, May 16th. Eleven analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $79.85.

About AnaptysBio

AnaptysBio, Inc is a clinical-stage biotechnology company focused on the discovery and development of therapeutic antibody product candidates in immunology and inflammation. Founded in 2012 and headquartered in San Diego, California, AnaptysBio leverages a proprietary somatic hypermutation platform to rapidly generate and refine human antibodies with optimized efficacy and safety profiles. The company’s technology is designed to accelerate target validation and candidate selection across a range of immune-mediated conditions.

The company’s pipeline includes multiple clinical-stage programs addressing dermatological and inflammatory disorders.